Effects of Prolonged Dual Antiplatelet Therapy in ST-Segment Elevation vs. Non-ST-Segment Elevation Myocardial
Jihoon Kim1, Young Bin Song1, Ju-Hyeon Oh2
1Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine.
Insights
Prolonged dual antiplatelet therapy (DAPT) for over 12 months significantly reduces recurrent myocardial infarction (MI) or stent thrombosis in acute coronary syndromes. This benefit was observed consistently across ST-segment elevation MI (STEMI) and non-STEMI (NSTEMI) patients.
Area of Science:
- Cardiology
- Interventional Cardiology
- Clinical Trials
Background:
- Dual antiplatelet therapy (DAPT) duration is crucial for managing acute coronary syndromes (ACS).
- Limited data exist on prolonged DAPT benefits and risks across different ACS types.
- Investigating DAPT consistency in ST-segment elevation myocardial infarction (STEMI) versus non-STEMI (NSTEMI) is essential.
Purpose of the Study:
- To compare the efficacy and safety of prolonged DAPT (≥12 months) versus standard DAPT (6 months) in ACS patients.
- To determine if the treatment effect of prolonged DAPT is consistent between STEMI and NSTEMI patients.
- To analyze the impact of prolonged DAPT on recurrent myocardial infarction (MI), stent thrombosis, and bleeding events.
Main Methods:
- Post hoc analysis of the SMART-DATE trial involving 1,023 STEMI and 853 NSTEMI patients.
- Comparison of outcomes between patients receiving ≥12 months of DAPT versus 6 months of DAPT.
- Primary outcome: composite of recurrent MI or stent thrombosis at 18 months.
- Secondary outcome: Bleeding Academic Research Consortium (BARC) Type 2-5 bleeding.
Main Results:
- Prolonged DAPT (≥12 months) significantly reduced the composite endpoint of recurrent MI or stent thrombosis compared to 6-month DAPT (1.2% vs. 3.8%; HR 0.31, P=0.012).
- This reduction was consistent in both NSTEMI (HR 0.20, P=0.140) and STEMI patients (Pinteraction=0.718).
- Prolonged DAPT increased BARC Type 2-5 bleeding in both STEMI (4.4% vs. 2.0%; HR 2.18, P=0.041) and NSTEMI (5.1% vs. 2.2%; HR 2.37, P=0.031) patients (Pinteraction=0.885).
Conclusions:
- Extended DAPT beyond 6 months effectively reduces ischemic events like recurrent MI or stent thrombosis in ACS patients.
- The benefits of prolonged DAPT on ischemic events are consistent across STEMI and NSTEMI presentations.
- While effective, prolonged DAPT is associated with an increased risk of bleeding events in both STEMI and NSTEMI patients.
Background:
The benefits and risks of prolonged dual antiplatelet therapy (DAPT) have not been studied extensively across a broad spectrum of acute coronary syndromes. In this study we investigated whether treatment effects of prolonged DAPT were consistent in patients presenting with ST-segment elevation myocardial infarction (STEMI) vs. non-STEMI (NSTEMI).
Methods And Results:
As a post hoc analysis of the SMART-DATE trial, effects of ≥12 vs. 6 months DAPT were compared among 1,023 patients presenting with STEMI and 853 NSTEMI patients. The primary outcome was a composite of recurrent myocardial infarction (MI) or stent thrombosis at 18 months after the index procedure. Compared with the 6-month DAPT group, the rate of the composite endpoint was significantly lower in the ≥12-month DAPT group (1.2% vs. 3.8%; hazard ratio [HR] 0.31, 95% confidence interval [CI] 0.12-0.77; P=0.012). The treatment effect of ≥12- vs. 6-month DAPT on the composite endpoint was consistent among NSTEMI patients (0.2% vs. 1.2%, respectively; HR 0.20, 95% CI 0.02-1.70; P=0.140; Pinteraction=0.718). In addition, ≥12-month DAPT increased Bleeding Academic Research Consortium (BARC) Type 2-5 bleeding among both STEMI (4.4% vs. 2.0%; HR 2.18, 95% CI 1.03-4.60; P=0.041) and NSTEMI (5.1% vs. 2.2%; HR 2.37, 95% CI 1.08-5.17; P=0.031; Pinteraction=0.885) patients.
Conclusions:
Compared with 6-month DAPT, ≥12-month DAPT reduced recurrent MI or stent thrombosis regardless of the type of MI at presentation.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Acute Coronary Syndrome I: Introduction
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care